AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol (February 15, 2008). doi:10.1152/ajplung.00417.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/4/L686    most recent
00417.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rentsendorj, O.
Right arrow Articles by Pearse, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rentsendorj, O.
Right arrow Articles by Pearse, D. B.
Submitted on October 9, 2007
Accepted on February 13, 2008

Role of vasodilator-stimulated phosphoprotein in cGMP-mediated protection of human pulmonary artery endothelial barrier function

Otgonchimeg Rentsendorj1, Tamara Mirzapoiazova2, Djanybek Adyshev2, Laura E. Servinsky1, Thomas Renne3, Alexander D Verin4, and David B. Pearse1*

1 Medicine, Division of Pulmonary and Critical Care, Johns Hopkins University, Baltimore, Maryland, United States
2 Medicine, University of Chicago, Chicago, Illinois, United States
3 Institute for Clinical Biochemistry and Pathobiochemistry, Julius-Maximilians-University, Wurzburg, Germany
4 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, United States

* To whom correspondence should be addressed. E-mail: dpearse{at}jhmi.edu.

Increased pulmonary endothelial cGMP was shown to prevent endothelial barrier dysfunction through activation of protein kinase G (PKGI). Vasodilator-stimulated phosphoprotein (VASP) has been hypothesized to mediate PKGI barrier protection because VASP is a cytoskeletal phosphorylation target of PKGI expressed in cell-cell junctions. Unphosphorylated VASP was proposed to increase paracellular permeability through actin polymerization and stress fiber bundling; a process inhibited by PKGI-mediated phosphorylation of Ser157 and Ser239 . To test this hypothesis, we examined the role of VASP in the transient barrier dysfunction caused by H2O2 in human pulmonary artery endothelial cell (HPAEC) monolayers studied without and with PKGI expression introduced by adenoviral infection (Ad.PKG). In the absence of PKGI expression, H2O2 (100-250 µM) caused a transient increased permeability and pSer157 -VASP formation that were both attenuated by protein kinase C inhibition. Potentiation of VASP Ser157 phosphorylation by either phosphatase 2B inhibition with cyclosporin or protein kinase A activation with forskolin prolonged, rather than inhibited, the increased permeability caused by H2O2. With Ad.PKG infection, inhibition of VASP expression with siRNA exacerbated H2O2-induced barrier dysfunction but had no effect on cGMP-mediated barrier protection. In addition, expression of a Ser-double phosphomimetic mutant VASP failed to reproduce the protective effects of activated PKGI. Finally, expression of a Ser-double phosphorylation-resistant VASP failed to interfere with the ability of cGMP/PKGI to attenuate H2O2-induced disruption of VE-cadherin homotypic binding. Our results suggest that VASP phosphorylation does not explain the protective effect of cGMP/PKGI on H2O2-induced endothelial barrier dysfunction in HPAEC.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.